MedTrace Logo

EPI-743 in Friedreich's Ataxia Point Mutations

NCT01962363 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2016-06-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of EPI-743 in patients with Friedreich's Ataxia point mutations

Conditions

Interventions

DRUG

EPI-743

EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.

Sponsors & Collaborators

  • Edison Pharmaceuticals Inc

    collaborator INDUSTRY

  • Friedreich's Ataxia Research Alliance

    collaborator OTHER

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa A Zesiewicz, MD · University of South Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01962363 on ClinicalTrials.gov